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Protein–protein interactions (PPIs) are increasingly important targets for drug discovery. Efficient
fragment-based drug discovery approaches to tackle PPIs are often stymied by difficulties in the production
of stable, unliganded target proteins. Here, we report an approach that exploits protein engineering to
“humanise” thermophilic archeal surrogate proteins as targets for small-molecule inhibitor discovery and to
exemplify this approach in the development of inhibitors against the PPI between the recombinase RAD51
and tumour suppressor BRCA2. As human RAD51 has proved impossible to produce in a form that is
compatible with the requirements of fragment-based drug discovery, we have developed a surrogate protein
system using RadA from Pyrococcus furiosus. Using a monomerised RadA as our starting point, we have
adopted two parallel and mutually instructive approaches to mimic the human enzyme: firstly by mutating
RadA to increase sequence identity with RAD51 in the BRC repeat binding sites, and secondly by generating
a chimeric archaeal human protein. Both approaches generate proteins that interact with a fourth BRC
repeat with affinity and stoichiometry comparable to human RAD51. Stepwise humanisation has also allowed
us to elucidate the determinants of RAD51 binding to BRC repeats and the contributions of key interacting
residues to this interaction. These surrogate proteins have enabled the development of biochemical and
biophysical assays in our ongoing fragment-based small-molecule inhibitor programme and they have
allowed us to determine hundreds of liganded structures in support of our structure-guided design process,
demonstrating the feasibility and advantages of using archeal surrogates to overcome difficulties in handling
human proteins.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Currently available drugs are mainly active against
a subset of “druggable” protein domains. Such bias
limits the development of new therapies and leaves a
pressing need for the identification of novel targets
[1]. Protein–protein interaction (PPI) interfaces rep-
resent a class of binding sites that play key roles in
all biological processes, accounting for approximate-
ly 130,000 binary interactions in human [2]. These
are regarded as a huge reservoir of potential newAuthors. Published by Elsevier Ltd. T
rg/licenses/by/4.0/).targets by modern pharmacology, provided that
specific limitations can be overcome; as opposed
to enzyme active sites, PPI interfaces are large,
almost featureless, and generally have not evolved
to bind small ligands [3]. They may thus appear
unsuitable as drug targets at first glance [4,5].
Nevertheless, the advent of a combination of
structural biology methods and extensive computa-
tional analyses has helped to develop potent PPI
binders, a number of which have reached clinical
phase trials during the last decade [6].his is an open access article under the CC BY license
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4590 Engineering archeal RAD51 surrogate systemsSuccessful development of PPI inhibitors also
implicates the possibility to inhibit the activity of
multiprotein complexes regulating DNA repair, cell
division, and other fundamental cellular processes.
Although these macromolecular machineries are
attractive drug targets, their complexity can be
seen as a practical limitation for the development
of inhibitors. In this respect, our purpose was to
demonstrate that fragment-based drug discovery
methods could be successfully used to target those
PPIs that lie at the core of large regulatory multi-
protein complexes. We focused our attention on
human RAD51, an ATP-dependent recombinase
crucial for homologous recombination (HR) [7] and
for error-free repair of DNA double-strand breaks.
RAD51 is also required in normal cells to enable
correct cell division; RAD51 deletion is embryonic
lethal in vertebrates, whereas its conditional knock-
out leads to rapid mitotic failure due to chromosomal
aberrations [8,9]. Inhibitors against RAD51 could be
used as therapeutic agents to treat cancer, either
alone or in conjunction with DNA-damaging agents
or ionising radiation.
Together with archeal RadA and bacterial RecA,
RAD51 forms a larger class of recombinases, which
share many structural and functional characteristics
[10], most notably the ability to oligomerise on DNA
substrates to form ordered nucleoprotein filaments
(NFs). NFs catalyse the reactions leading to the
homologous strand pairing and strand-exchange that
underlie HR. In human cells, the correct execution of
RAD51-dependent HR requires the concerted effort of
several accessory proteins, including the BRCA2
tumour suppressor. The inheritance of germline
mutations affecting BRCA2 predisposes to breast,
ovary, pancreas, and prostate cancers (reviewed in
Ref. [11]). BRCA2 binds directly to RAD51 through
eight ~35-residue-long motifs, the BRC repeats,
whose sequence and spacing are evolutionarily
conserved within a large ~1000-residue region of
BRCA2. BRCA2-deficient cells fail to form nuclear
RAD51 foci at the sites of DNAdamage [12,13], due to
the loss of essential functions of BRCA2 in regulating
RAD51 dynamics [14] and nuclear–cytoplasmic
transport [15]. In vitro, RAD51-dependent HR reac-
tions under physiologic ionic conditions are promoted
by the BRC repeats [16], which work to enhance the
nucleation and stability of RAD51 assembly on
single-stranded DNA whilst inhibiting the premature
formation of RAD51:double-stranded DNA assem-
blies [17–21]. BRCA2-deficient cells exhibit increased
sensitivity to radiation and chemical DNA-damaging
agents [13,22,23]. Moreover, there is evidence
that RAD51 is overexpressed in certain cancer cells,
where expression levels correlate with the aggres-
siveness of the tumour and its resistance to chemo-
therapy [24]. These findings suggest that small
molecules targeting the BRCA2–RAD51 interaction
may be useful in new approaches for cancer therapy.The overall structural architecture is conserved
between the eukaryotic RAD51 and archeal RadA
[25–28]. The recombinase is composed of two
globular domains: an N-terminal helical domain that
facilitates DNA binding and an AAA+ family
nucleotide-binding domain with ATPase activity
(Fig. 1a). These are joined by a linker carrying a
conserved FxxA epitope that drives self-association
[26,27,29]. TheconservedPheandAla residues of the
FxxA motif bind in two small pockets on the ATPase
domain, across the central β-sheet [30]. Downstream
of the alanine, the linker folds into a short helix
and establishes further interactions with an aromatic
residue (Tyr or Phe; Fig. 1c) in a shallow pocket of the
catalytic domain (the oligomerisation groove) [26].
The structure of RAD51 in complex with the fourth
BRC repeat (BRC4) of BRCA2 provided a mecha-
nistic explanation for the control exerted by BRCA2.
TheBRC repeat adheres toRAD51 in away similar to
a “Velcro” strip: through a large number of indepen-
dent contacts over a wide surface. In analogy to the
RAD51 oligomerisation linker, the N-terminus of
BRC4 carries an FxxA motif that binds the RAD51
ATPase domain in the same FxxA pockets (see
above). The C-terminal portion of BRC4 instead folds
over the other side of RAD51, using a conserved
LFDE motif to bind to what we call the LFDE pocket
[25,31]. In vitro, high concentrations of isolated BRC4
peptide are effective in disrupting RAD51 oligomers
and NFs [32] and associate in cells with sensitivity to
DNA-damaging agents [23].
Notably, RAD51 spontaneously folds into a glob-
ular architecture and generates an interface that,
upon binding, induces the otherwise unstructured
BRC repeat to assume the optimal binding confor-
mation [33]. This is an example of a “concerted
folding and binding” process that immediately sug-
gested a strategy for a fragment-based drug discov-
ery approach [34]: preventing the concerted folding–
binding event through small molecules that target the
interaction hotspots on the RAD51 interface. This
seems preferable over targeting the whole complex
with interfacial inhibitors that lock the two partners
into a “dead-end binary complex” [35].
We pursued this strategy and developed small-
molecule inhibitors against the BRCA2–RAD51 inter-
action using fragment-based and structure-guided
approaches [36,37]. These required extensive, iterative
biophysical and crystallographic assessment of small
molecules binding to guide the design of high-potency
inhibitors. Therefore, the prerequisite for the success of
the whole project was the availability of RAD51 as a
stable and unliganded protein, and deprived from the
ability to form oligomers that would prevent any
fragment from binding to the target site. Such variant
of RAD51 was not available at the beginning of the
project and, despite extensive efforts, any attempt to
generate it using the human protein failed [38]. We
therefore explored the possibility of using amore stable
(a)
(c) (d) (e)
(b)
Fig. 1. Comparative analysis of HsRAD51 and PfRadA. (a) Domain structure of RAD51 with N-terminal domain in grey,
FxxA containing linker in blue, and ATPase domain in green. (b) Alignment of human RAD51 and P. furiosus RadA, with
different domains highlighted in the same colours as the structure in panel (a). Asterisks indicate identical residues
between the two proteins. (c–e) Comparison of conservation between RAD51 and RadA in and around the BRC4 binding
site in RAD51. (c) RAD51 (surface representation) in complex with BRC4 peptide (blue tube with side chains as sticks;
PDB: 1N0W) shows the BRC4 interacting residues in green on the surface. (d) Schematic map of the residues in the
extended BRC4 binding site and oligomerisation groove, with RadA residues labelled in green and orange for identical or
non-identical residues with RAD51, respectively, followed by RAD51 residue labels in green. Different parts of the BRC
repeat and oligomerisation epitope binding sites are highlighted in grey. For orientation, the positions of the labelled
binding sites are approximately in the equivalent positions in the two proteins at either side. (e) Structure of RadA ATP
domain (PDB: 1PZN, chain A) bound to the oligomerisation peptide (blue tube with side chains as sticks,). The surface of
RadA ATPase domain is coloured light green for identical residues with RAD51 and orange for non-identical residues. The
structures of (c) RAD51 and (e) RadA are shown in the same orientation after superpositioning.
4591Engineering archeal RAD51 surrogate systemsorthologue as a surrogate and focused our efforts on
archeal RadA from Pyrococcus furiosus, a protein that
was already structurally characterised and is closely
related to human RAD51 [26,39]. All RAD51/RadA
family recombinases self-associate through their
N-terminal FxxA motifs to form helical oligomers.
Such oligomeric structures are poorly suited for
biophysical screening or structural studies aiming to
characterise the interaction of potential inhibitors with
the oligomerisation interface.
Here, we describe the complete process of
generating robust, RAD51-like surrogate systems
from this archeal protein via two distinct approaches:
by stepwise mutation of the surface of the RadA to
humanise the BRC4 binding area (HumRadA series
of mutants) and by generating an archeal/human
chimera (ChimRAD51) in which all of the BRC4binding part of RAD51 is stabilised by parts of RadA.
We present thorough structural and biophysical
characterisation of the different surrogate proteins
and demonstrate their suitability for structure-guided
drug discovery, highlighting the potential of this
approach for other hard-to-analyse targets.Results
Humanisation of RadA
We have already reported the successful monomer-
isation of RadA previously, by removing the N-terminal
the FxxA epitope that governs self-association, and
shown that theC-terminal ATPase domain (RadA-ct) is
4592 Engineering archeal RAD51 surrogate systemscorrectly folded and able to bind ATP and short
FxxA-like peptides [30,38] (Fig. 1a). With a monomeric
RadA in hand, the BRC4 binding site on RAD51 was
analysed in more detail. The sequence identity
between human RAD51 (HsRAD51) and P. furiosus
RadA (PfRadA) in the C-terminal ATPase domain is
only 53%. Although the two proteins self-associate with
similar FxxA motifs (FHTA and FMRA, respectively;
Fig. 1b), their FxxA binding sites are not identical in
sequence and the LFDE sites are yet more divergent
(Fig. 1c). As protein–ligand interactions can be greatly
affected even by a single conservative mutation in the
binding site, significant mutagenesis of surface resi-
dueswasneeded to create aviable surrogate system in
which the target site would closely resemble the one of
HsRAD51.
We proceeded with the humanisation of RadA-ct in
a stepwise fashion, starting from the immediate
vicinity of the phenylalanine-binding pocket at the
FxxA site (Phe pocket) and progressing towards the
LFDE site (needed for high-affinity BRC4 binding)
and the oligomerisation groove, always changing
the RadA residues to corresponding human ones
(Fig. 1c and Table 1). Initial analysis suggested that
at least four residues surrounding the Phe pocket
needed to be mutated: I169M158, Y201A190, and
V202Y191, K221M210 (we will use RadA residue
numbers to match with the residue numbering in our
crystal structures, but indicate equivalent RAD51
residue numbers as a subscript). Mutation of these
residues in the monomerised form of RadA was used
to create the first humanised RadA protein (Hum-
RadA1). This minimally humanised RadA mutant
could be expressed and purified similar to the original
monomerised protein; its crystal structure confirms the
success of the mutagenesis and shows that the
binding site resembles that ofHsRAD51, with the side
chain of R204194 moving to the position found in
RAD51 (Supplementary Table 1 and Supplementary
Fig. 1). Thismutant served as the first crystallographic
model for the analysis of early fragment hits [37] and
for the characterisation of FxxA-like tetrapeptide
binding to RadA [30].
Residues E219S208 and D220A209 of PfRadA are
located between the FxxA and LFDE sites, with the
BRC peptide interacting with equivalent HsRAD51
residues. These were mutated to their human equiv-
alents to create HumRadA2. There was a marked
decrease in the thermal stability with this mutant, with
the midpoint of thermal denaturation being lowered to
85 °C (Supplementary Fig. 2). This is possibly due to
the disruption of an ionic interaction between E219208
and R270254, a hypothesis corroborated by the
crystallographic analysis of HumRadA2 (Fig. 2a).
Reduced stability, an unintended conssequence of
mutagenesis, proved to be beneficial, as it allowed the
measurement of full thermal denaturation curves
during fragment screening by differential scanning
fluorimetry (DSF) [37].The structure of HumRadA2 also highlighted the
need to introduce further mutations at the back of the
Phe pocket (particularly V232Y216) in order to force
I169M158 andK221M210 into the same conformation as
observed in the HsRAD51:BRC4 complex. Proper
humanisation of the Phe pocket also required the
removal of an insertion that lies just before V232216
(residues L226–P231).
Structural analysis confirmed that these mutations
had granted a better resemblance to the HsRAD51
FxxA pocket (Supplementary Fig. 1), making the
resulting proteins HumRadA3 and HumRadA4
suitable for fragment-based approach to inhibitor
design. Nevertheless, given the poor conservation of
the LFDE pocket, those mutants still lacked the ability
to bind BRC4. Interaction with BRC4 was essential
both for the validation of the surrogates and for the
development of a robust competition assay that would
serve a screening campaign later. Therefore, we
proceeded with a stepwise humanisation of the LFDE
site and validated the resulting mutants using bio-
physical methods (as described in the next section).
Extensive humanisation made the protein progres-
sively more difficult to purify and manipulate, but it
often led to no significant change in the interactionwith
BRC4 until the right combination of mutations syner-
gistically improved the affinity for BRC4. Many of the
intermediate mutants were therefore not characterised
in detail. The synergistic effect was particularly evident
in mutant HumRadA14, with seven additional muta-
tions compared to HumRadA5. HumRadA14 repre-
sents a “turning point”of the humanisation process as it
is the first mutant to show detectable binding to BRC4
peptides, due to a combination of fine-tuning at the
LFDE site and further re-shaping of the Phe pocket
(mutations V168A157 and W170Y179; Supplementary
Fig. 1). Charge mutations A226R250 and K198D187 (in
HumRadA16 and 18, respectively) increased the
BRC4 binding affinity and were combined in the
following mutants. The humanisation series could
have ended with HumRadA22, which displays a fully
humanised BRC4 binding surface. Nevertheless, we
extended the humanisation process further into the
oligomerisation groove and “behind” the Ala pocket, in
anticipation of the inhibitor design process expanding
beyond the core of the FxxA binding site. This created
our most humanised surrogate RadA, HumRadA33.
Isothermal titration calorimetry (ITC) data confirmed
that this last set of mutations ensured selectivity of
HumRad33 for the human oligomerisation epitope
over the archeal one (Table 1). The complete progress
of convertingRadA intoRAD51-like protein is shown in
Fig. 3a, with the illustration of the surface of Hum-
RadA33 displaying continuous identity with RAD51.
The crystal structure of HumRadA22 confirmed the
success of the humanisation process and shows good
agreement with the human RAD51 structure (Fig. 3b).
Overall, the structures of the humanisedRadAproteins
are very similar to each other (Supplementary Fig. 2),
Table 1. Details of HumRadA mutants and summary of binding data
Mutant Mutations
(all constructs carry also deletion of the L2 loop)
Tm (°C) BRC4
affinity
(nM)/FP
RadA-OP
affinity
(μM)/ITC
RAD51-OP
affinity
(μM)/ITC
HumRadA1 I169M,Y201A, V202Y, K221M 94.3 n.d. 1.8 ± 0.5 24 ± 5
HumRadA2 I169M, Y201A, V202Y, E219S, D220A, K221M 82.1 weak 3.4 ± 0.3 n.d.
HumRadA3 I169M, Y201A, V202Y, E219S, D220A, K221M, I222M, V223M, V232Y n.d. n.d. n.d. n.d.
HumRadA4 I169M, Y201A, V202Y, E219S, D220A, K221M,
I222M, deletion of 227–231,V232Y, K233A
n.d. n.d. n.d. n.d.
HumRadA5 I169M, Y201A, V202Y, L213Q, V215L, Q216Y,
E219S, D220A, K221M, D267M, L274E, Y275F
80.8 weak n.d. n.d.
HumRadA14 V168A, I169M, W170Y, Y201A, V202Y, L213Q,
V215L, Q216Y, E219S, D220A, K221M, I222M,
K223V, L225S, V232Y, H264F, D267M,
L274E, Y275F
78.4 670 ± 12 n.d. n.d.
HumRadA16 V168A, I169M, W170Y, Y201A, V202Y, L213Q,
V215L, Q216Y, E219S, D220A, K221M, I222M,
K223V, L225S, V232Y, K263R, H264F, A266R,
D267M, L274E, Y275F
77.2 294 ± 6 n.d. n.d.
HumRadA18 V168A, I169M, W170Y, K198D, H199N, I200V,
Y201A, V202Y, L213Q, V215L, Q216Y, E219S,
D220A, K221M, I222M, K223V, L225S,
V232Y, K263R, H264F, D267M, L274E, Y275F
76.1 10.7 ± 0.35 n.d. n.d.
HumRadA20 V168A, I169M, W170Y, K198D, H199N, I200V,
Y201A, V202Y, L213Q, V215L, Q216Y, E219S,
D220A, K221M, I222M, K223V, L225S, V232Y,
K263R, H264F, A266R, D267M, L274E, Y275F
75.5 3.90 ± 0.15 n.d. n.d.
HumRadA22 V168A, I169M, W170Y, I182L, K198D, H199N, I200V, Y201A, V202Y, L213Q, V215L, Q216Y, E219S,
D220A, K221M, I222M, K223V, L225S, V232Y, K263R, H264F, A266R, D267M, L274E, Y275F
74.0 6.20 ± 0.30 n.d. n.d.
HumRadA33 S167K, V168A, I169M, W170Y, N175G, I182L, R183L, D192S, P193G D194S, E195D, K198D,
H199N, I200V, Y201A, V202Y, L213Q, V215L, Q216Y, E219S, D220A, K221M, I222M, K223V,
L225S, V232Y, K263R, H264F, A266R, D267M, L274E, Y275F
n.d. n.d. 14 ± 2 0.8 ± 1
HumRadA22F V168A, I169M, W170Y, I182L, K198D, H199N,
I200V, Y201A, V202Y, K221M
n.d. n.d. n.d. n.d.
HumRadA26F S167K, V168A, I169M, W170Y, N175G, I182L, R183L, K198D, H199N, I200V, Y201A,
V202Y, E219S, K221M, I222M,
n.d. n.d. n.d. n.d.
HumRadA28F S167K, V168A, I169M, W170Y, N175G, I182L,
K198D, H199N, I200V, Y201A, V202Y, L213Q,
V215L, Q216Y, E219S, K221M, I222M, K223V,
L225S, V232Y, K263R, H264F, A266R, D267M,
L274E, Y275F
n.d. n.d. n.d. n.d.
HumRadA33F S167K, V168A, I169M, W170Y, N175G, I182L,
R183L, D192S, P193G D194S, E195D, K198D,
H199N, I200V, Y201A, V202Y, E219S,
K221M, I222M, K223V, V232Y
n.d. n.d. n.d. n.d.
A list of all the humanised RadA mutants described in the article, with the mutations they carry (numbering as per PfRadA sequence) and the details of thermal stability (measured by DSF)
and affinities towards BRC4 and RadA and RAD51 oligomerisation (OP) peptides, measured by ITC. It is worth noting the decreasing thermal stability as humanisation progresses and the
increasing affinity towards BRC4 and RAD51-OP peptides. Mutations introduced for the first time are highlighted in bold. n.d. – not determined.
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Fig. 2. Humanisation of RadA and validation of mutants with different ligands. (a) Details of ionic interaction between E219
andR270 inHumRadA1 (orange) and the equivalent residues inHumRadA2 (green), causing reduction in the thermal stability
of the protein. (b) Thermal shift analyses of different HumRadA mutants in the presence of BRC4 (blue), RadA-OP (yellow),
and RAD51-OP (green) peptides and with ATP-Mg2+ (red). (c) Mutations A266R250 and K198D187 (introduced in
HumRadA16 and HumRadA18, respectively) reinstate the interactions existing in the HsRAD51:BRC4 complex that promote
the tight binding of the peptide. RAD51 structure is shown in green and RadA in orange, with BRC4 repeat in blue. RAD51
structure is shown in green and RadA in orange, with BRC4 repeat in blue. (d) Binding isotherm of ITC titration of RAD51
oligomerisation peptide into HumRadA33. (e) Binding isotherm of ITC titration of BRC4 peptide into HumRadA33. ITC data for
other peptide binding ITC measurements are found in Fig. S3. (f) Structure of HumRadA1 in complex with RadA-OP peptide.
The peptide (in blue) is shown as sticks on theHumRadA2molecular surface. Thewhite sticks show the corresponding region
of the oligomerisation sequence from PfRadA heptameric structure (PDB: 1PZN, chain A).
4594 Engineering archeal RAD51 surrogate systemsand significant differences can only be seen in loops
that are involved in either crystal packing, or aremobile
and poorly defined.
The structures of those mutants, where the LFDE
site has been humanised (HumRadA14 and 22),
show good correlation with the human BRC4–RAD51
complex in this area for the backbone but some
variation in the side-chain conformations (Fig. 3b and
Supplementary Fig. 2e and f). Despite extensive
efforts, we were unable to obtain a crystal structure of
a complex of a HumRadA mutant with a BRC repeat,
and differences in the BRC4 binding site are likely to
reflect the unliganded state of our proteins.
Table 1 summarises all the mutants described in
this paper. In the most humanised form of RadA,
HumRadA33, a total of 32 residues have beenmutated in and around the BRC4 binding site in
RadA to resemble human RAD51. The resulting
protein has 65% sequence identity to human RAD51
in the ATPase domain and 100% identity in the
residues that interact with BRC4 and with the
oligomerisation epitope (Fig. 3a and b).
Table 1 also shows how the humanisation progres-
sively reduced protein stability. Nevertheless, even the
most humanised mutants were still very thermostable,
much more so than human RAD51 (Supplementary
Fig. 2).
Validation of humanised RadA mutants
The main objective of PfRadA humanisation was
to obtain a protein tailored for a fragment screening
(a)
(b)
Fig. 3. Characterisation and validation of humanised RadA mutants. (a) Surface representation of selected humanised
RadAmutants with surfaces coloured as in Fig. 1B, with humanising mutations coloured in dark green. HumRadA33 as the
final mutant is shown for completeness, but in the absence of its crystal structure, the humanisation is shown on the
structure of HumRadA22. (b) Superposition of the HumRadA22 and human RAD51 in the FxxA (left) and LFDE (right) sites
with each RadA residue coloured in green if it is identical to human residue. All RAD51 residues are shown in light grey,
with the key residues discussed in the text labelled following RadA residue numbering.
4595Engineering archeal RAD51 surrogate systemscampaign that would then enable the development
of inhibitors against the HsRAD51:BRCA2 interac-
tion. Therefore, the result of the humanisation had to
be a protein that mimicked the human enzyme as
closely as possible whilst providing a robust surro-
gate protein that was suitable for the biophysical and
structural characterisations of the inhibitors.
Different peptidic tools were used to validate the
progressof humanisation. A 16-aa peptide (RadA-OP)
corresponding to the oligomerisation interaction epi-
tope, as seen in the RadA heptameric crystal structure
[26], was used as a probe for RadA-like interactions at
the oligomerisation groove. A corresponding human
oligomerisation peptide (RAD51-OP) was used tofollow theprogressof humanisation. TheBRC4peptide
was used to assess the success of the humanisation of
the full BRC interaction site. As a reference value,
HsRAD51 has been reported to have nanomolar
affinity for BRC4 [40]; no previously published data
were available for the interactions with the oligomerisa-
tion peptides.
The humanisation process was expected to pro-
gressively increase the affinity of the surrogate
proteins for the RAD51-OP and, at the same time,
weaken the binding for the RadA-OP. Such change in
selectivity should be reflected into a different ability of
these peptides to stabilise the surrogate proteins upon
binding. DSF was used as a simple, high-throughput
4596 Engineering archeal RAD51 surrogate systemsmethod to verify the initial hypothesis across the
humanisation series. We have previously shown that
different RadA and RAD51 constructs show signifi-
cant stabilisation on binding to various nucleotides
[38], and ATP was used as a positive control in DSF
and to show that proteins are correctly folded (Fig. 2b).
DSF is also one of the methods used in primary
fragment screening, and this study also demonstrated
the feasibility of this method to detect subtle affinity
differences between ligands binding in this site. The
results of the DSF screening were then validated
using ITC by measuring the affinity of both RadA-OP
and RAD51-OP for key mutants (Table 1 and
Supplementary Fig. 3).
The binding of HumRadA proteins to RadA-OP (as
monitored by DSF; Fig. 2b) was largely unaffected by
mutations around the Phe pocket, and the affinity
towards RadA-OP was reduced only when we
fine-tuned the residues around the Ala pocket. In
particular, DSF showed that the introduction of the
K198D187 mutation reduced the ΔTm by over 1 °C. In
line with the expectations, the ITC experiments
demonstrated that the affinity for the RadA-OP,
being relatively robust for HumRadA1 (KD = 1.8 ±
0.5 μM), wasweakenedby an order ofmagnitudewith
the most advanced versions of the surrogate system
(HumRadA33, KD = 14 ± 2 μM). Conversely, the
affinity for the RAD51-OP increased compared to
the early stages of the process (HumRadA1, KD =
24 ± 5 μM), reaching submicromolar values for
HumRadA33 (KD = 0.8 ± 0.1 μM; Fig. 2d). We have
also determined the crystal structure of HumRadA1 in
complexwithRadA-OP,which shows that the isolated
oligomerisation peptide binds to the ATPase domain
in a very similar way to what is observed in the
heptameric ring structure of PfRadA (Fig. 2f). The
FxxA epitope straddles the central β-sheet, and the
C-terminal end of the peptide folds into a short α-helix
interacting with the oligomerisation groove. All the
peptide residues that interact with the domain are in
identical positions to those found in the oligomeric
RadA.
Finally, it was necessary to demonstrate that the
humanisation made PfRadA mutants increasingly
more competent for BRC4 binding as the peptide
binding surface becomesmore humanised. DSF, ITC,
and fluorescence polarisation (FP) assay with a
fluorescently labelled BRC4 peptide were used to
probe the interaction with the key representative
mutants (Fig. 2b–e). As predicted, the affinity towards
BRC4 increased gradually, reflecting the progression
of the humanisation (Fig. 2b, Table 1, and Supple-
mentary Fig. 4). In agreement with the DSF results,
themutations introduced at the edge of the Ala pocket
in HumRadA18 (K198D187/H199N188/I200V189)
considerably facilitated the interaction with BRC4,
increasing the affinity by an order of magnitude. A
further gain in affinity was obtained in HumRadA20 by
the introduction of A266R250 mutation in the LFDEsite. The majority of these mutations aimed to
reconstitute electrostatic interactions occurring be-
tween HsRAD51 and the BRC4. For instance, the
acidic group in D198187 probably reinstated a polar
interaction with BRC residue S1528, whilst the
A266R250 mutation reintroduced a basic residue that,
in HsRAD51, forms a salt bridge with the BRCA2
residue E1548 (Fig. 2c). The final humanised mutant,
HumRadA33, has a Kd of 33 nM by ITC for BRC4
peptide (Fig. 2e).
The FxxA motif with the two hydrophobic residues
is regarded the key epitope driving the formation of
the BRC4:RAD51 complex. However, the results
described in this section also highlight the functional
relevance of the BRC4 C-terminal region, which
establishes interactions ensuring the tight binding of
the repeat to the recombinase [31]. Analysis of the
roles of D187andR250 in humanRAD51 reveals how
significant the contribution of these polar interactions
is to BRC4 binding, both in the FxxA and the LFDE
sites. These aspects of RAD51–BRC4 interaction
have not been always appreciated and illustrate the
importance of taking into account the whole interac-
tion surface, and not just the hot-spots, when
designing surrogate systems for PPIs.
RadA/RAD51/RadA chimera
In parallel with the stepwise humanisation of RadA,
we explored a second approach to creating a
surrogate RAD51. In HsRAD51, all the residues that
form the BRC4 binding surface are contiguous in
sequence within the ATPase domain, and the N- and
C-terminal regions of this domain come together to
form the rest of the globular structure (Fig. 4a). Also,
the residues interfacing between the BRC4 binding
segment and the N- and C-terminal parts of the
ATPase domain are nearly identical between the
RadA and RAD51. In the hope that RadA-derived
sequences could stabilise the otherwise unstable
human RAD51, an artificial archeal human chimeric
construct (ChimRAD51) was designed, in which the
entire BRC4 interacting part of human RAD51
(residues 156–261) is fused to the N- and C-terminal
segments of the PfRadA ATPase domain (residues
108–165 and 278–349, respectively; Fig. 4a). We
envisaged that this engineered protein, in which only a
small and distal part of the protein was derived from
RadA,would retain human-like binding affinity towards
BRC4 whilst benefiting from the stabilisation, due to
the PfRadA segments, and that this chimeric system
could provide an independent comparison and vali-
dation of the humanisation approach.
Perhaps not surprisingly, when expressed in
Escherichia coli, ChimRAD51 was insoluble, reflect-
ing the difficulties in working with the human enzyme.
As the original RAD51:BRC4 structure was deter-
mined using a fusion construct between the BRC4
repeat and C-terminal ATPase domain of RAD51,
(a) (a)
(c) (d)
Fig. 4. Design and validation of the chimeric RAD51 protein. (a) Domain structure of RAD51:BRC4 complex highlighting
the parts that make up the chimeric protein. RadA N- and C-terminal parts are coloured orange and beige, respectively,
with the central part of RAD51 in green. The diagram below shows the complete expression construct with His6-GST
fusion, BRC4 protein with TEV cleavage site, and the ChimRAD51. (b) Thermal denaturation curves for BRC4–RAD51
(green) and BRC4–ChimRAD51 (red) following CD signal at 208 nm. (c) FP binding assay between ChimRAD51 and the
fluorescently labelled BRC4 peptide. Each of the three curves and associated measurements represents an independent
experiment. (d) Competition FP measurement using unlabelled BRC4 peptide to complete the Alexa Fluor 488-labelled
peptide. Data are shown for two independent titrations, and the blue line is fitted to the average.
4597Engineering archeal RAD51 surrogate systemsjoined by a flexible linker [25], an analogous construct
was made using ChimRAD51, with the introduction of
a tobacco etch mosaic virus (TEV) protease cleavage
site to facilitate the separation of ChimRAD51 from the
BRC4 repeat (Fig. 4a). This construct, like the original
BRC4–RAD51 fusion, was expressed solubly in
E. coli, and the protein could be purified to homoge-
neity using either His-glutathioneS-transferase (GST)
or His-tag fusions.
To evaluate the success of our attempt to engineer
a more stable protein, the BRC4–ChimRAD51
fusion was compared with the analogous BRC4–
RAD51 fusion construct. Measured by CD, BRC4–
ChimRAD51 fusion protein has an apparent Tm of
64 °C, a very significant 13 °C stabilisation over the
human BRC4–RAD51 fusion (Fig. 4a). This demon-
strated that the N- and C-terminal parts of the archeal
protein increase the thermal stability of the protein
significantly. However, it was still necessary to
separate the BRC4 peptide and ChimRAD51. Unfor-
tunately, the two remained stably associated afterTEV cleavage and could not be separated without
strong denaturing agents (Supplementary Fig. 5). In a
final modification to the system, we weakened the
BRC4:ChimRAD51 interaction by mutating the con-
served phenylalanine 1524 in BRC4 to alanine. This
mutant was still solubly expressed in bacteria, and we
were able to separate the unliganded ChimRAD51
from the proteolytically released BRC4 peptide under
native conditions in size-exclusion chromatography.
Using FP experiments, we could show that the
BRC4 peptide binds to ChimRAD51 with nanomolar
affinity (KD = 4 ± 1 nM, Fig. 4c), a result that was
confirmed by competition experiments (Fig. 4d). Both
the direct binding isotherms and the competition
assays were highly reproducible and invariant over
time (≥1-h incubation; Supplementary Fig. 5) andwere
satisfactorily described by a single-site interaction
model. Following final validation via ITC (Supplemen-
tary Fig. 5b), it was concluded that the ChimRAD51
retained the ability to tightly bind BRC4 in a simple 1:1
fashion, thus providing a faithful mimicry of the
4598 Engineering archeal RAD51 surrogate systemsrecombinase–peptide binding event in the absence of
any oligomerisation process. The 10-fold higher affinity
for ChimRAD51 in comparison to full-lengthHsRAD51
[40] can be explained by the monomeric state of
ChimRAD51 and the lack of the N-terminal domain,
which has been proposed to participate in BRC4
binding. We are therefore confident that ChimRAD51
is a bona fide surrogate of HsRAD51 in its unliganded
form, and it became our primary screening tool. Being
more stable than its human counterpart and practica-
ble for FP and ITC experiments, this protein is suitable
for fragment-based approaches, where various bio-
physical techniques are used to screen fragment
libraries and analyse newly created molecules in
iterative cycles of validation, design, and optimisation.
In the context of a drug discovery programme,we have
used ChimRAD51 to establish an FP-based compe-
tition assay in 384-well format for a rapid and reliable
screening of molecules capable of displacing BRC4
from RAD51 (Supplementary Fig. 5c).
Oligomeric surrogate proteins
Full-length RAD51 and RadA form oligomers in
solution, and in the case of RAD51, these oligomers
can be disrupted by BRC4 [32]. A faithful surrogate of
human RAD51 should show the same behaviour, if
provided with the structural determinants that induce
oligomerisation. As a final validation, we generated
full-length variants of HumRadA22 (flHumRadA22)
and ChimRAD51 (flChimRAD51), by adding to them
the missing N-terminal parts (with the oligomerisation
sequences) from RadA and RAD51, respectively.
Dynamic light scattering (DLS) experiments (Supple-
mentary Fig. 6) confirmed that the full-length surro-
gates formed oligomers in solution. When BRC4
repeat peptide was added into the samples, the
oligomeric proteins showed dose-dependent dissoci-
ation and shift to smaller molecular size. This
demonstrated that both approaches in creating
human-like surrogates were also able to reproduce
the functional effect of the BRC4 repeat on an
oligomeric protein.
Development of a crystallographic platform
using humanised RadA
We were unable to crystallise ChimRAD51, and
many of the more advanced humanised HumRadA
constructs failed to yield crystals of sufficient quality
for structure-guided drug design. We therefore
returned to the earlier surrogates (HumRadA1–3;
Fig. 5) that crystallised readily in conditions similar to
those originally identified for monomeric RadA-ct. As
we were targeting the PPI between RAD51 and the
BRC4 peptide, the mutated residues were invariably
on the surface of the protein. As a result,mutants often
crystallised in different crystal forms, and accessibility
of the FxxA binding pocket varied significantly(Fig. 5a). For instance,mutantHumRadA1crystallises
in one monoclinic (P21) and two orthorhombic
(P212121 and P21212) space groups with little similar-
ity in crystal contacts, but we could control the
obtained crystal forms through cross-seeding with
seeds from crystals of different mutants.
To test the suitability of a given crystal form for
soaking experiments, we used the tetrapeptide FHTA
(corresponding to the FxxA motif of the BRC4 repeat)
as a sizeable test compound of 516 Da. It was
possible to soak the peptide at relatively low concen-
trations (2–5 mM) into RadA-ct crystals and into the
orthorhombic form of HumRadA1, as verified by
structures determined using these crystals [30]. The
ability to soak peptides into the crystals gave
confidence that soaking for fragment-based drug
design would be successful.
Whilst it was possible to obtain apo crystals of the
fully humanised mutants (HumRadA22), the crystals
were difficult to grow and handle and hence not well
suited for drug discovery purposes. As the reduced
crystallisability seemed to be a consequence of
humanisation of the LFDE site, we decided to
reverse these mutations and created two surrogates
(HumRadA22F and HumRadA33F) for crystallo-
graphic purposes. These proteins were fully huma-
nised in the extended FxxA binding area and in the
oligomerisation groove, but these proteins contained
the RadA-like LFDE site (see also Fig. 1 for
reference to the relative position of these structural
elements). They were easier to purify than their
corresponding fully humanised mutants Hum-
RadA22 and HumRadA33, and they readily formed
crystals that yielded high-quality diffraction data and
tolerated up to 10% dimethyl sulphoxide (DMSO)
during small-molecule soaking experiments.
Of all the RadA variants examined, it turned out that
the original wild-type RadA-ct construct crystallised in
the most suitable crystal form, with a fully open FxxA
binding site (Fig. 5a). These crystals were used as
seeds to drive HumRadA22F protein into the same
crystal form. This cross-seeding, which we had used
with other and more closely-related mutants before,
was successful and provided a system where the
entire target site was fully humanised, open, and
unobscured by crystal contacts (Fig. 5a). These
crystals of HumRadA22F were finally validated by
soaking the FHTA tetrapeptide into the crystal, which
demonstrated that drug-sized molecules can diffuse
into these crystals and bind to the target site (Fig. 5b).
Crystallographic fragment screen
To demonstrate the robustness of our crystallo-
graphic system for drug discovery purposes, we
used HumRadA22F crystals to perform a direct
X-ray crystallographic screening of a library contain-
ing 352 fragments, and we soaked 88 cocktails of 4
fragments into these crystals. We were able to collect
(a) (b)
Fig. 5. Crystallographic system using humanised RadA. (a) Crystal packing in various crystal forms obtained for
humanised RadA proteins. Protein with molecular surface represents the solved structure, and the ribbon diagrams are the
symmetry-relatedmolecules in the crystal lattice next to the FxxAsite.Contacts between the proteins in the lattice are coloured
red on the surface of the central molecule. The transparent blue ellipse indicates the FxxA binding site in the central molecule.
(b) FxxA binding site with superimposed FHTA peptide in the wild-type-like crystal form of the HumRadA22Fmutant. (c) Two
examples of fragment hits from crystallographic fragment cocktail screen using HumRadA22F crystals, binding in the Phe
pocket (thin surface outline). Final 2Fobs-Fcalcc electron densities are rendered at 1σ.
4599Engineering archeal RAD51 surrogate systemsdiffraction data from all of the soaked crystals to
typically 1.6–1.8 Å resolution or better (up to 1.3 Å),
despite handling crystals in a high-throughput fashion.
Approximately 50% of structures showed the binding
of an unspecific ring system in the Phe pocket, of
which we classified 15 as hits, that is, 17% of the
crystal structures showed a discernible compound
bound,whichequates to anoverall hit rate of 4%. For 3
of these 15 structures, it was not possible to uniquely
identify directly from the density which of the
cocktailed chemical entities had bound. These would
need deconvolution of the mixture by each of the
fragments as singletons. The remaining 12 hits could
be clearly identified from the density, which is owed to
structurally diverse cocktailing. Two representative
examples of well-defined fragments in the Phe pocket
are shown in Fig. 5c. Notably, we did not observe
fragment binding to any additional sites, particularly to
the Ala pocket, which is presumably too shallow and
devoid of hydrogen-bonding opportunities to provide
enough binding energy for small molecule to bind on
its own. The soaking procedure did not seem to have a
significant impact on crystal quality, suggesting that no
high-affinity fragment binding sites are obscured by
crystal contacts.Discussion
At the start of our drug discovery project to design
inhibitors against human recombinase RAD51, we
encountered several problems. The natural oligo-
merisation of RAD51 occludes the target site, and
the only known monomeric construct of RAD51 was
a fusion protein comprising RAD51 and a peptide
that binds to that same site with high affinity. It was
therefore necessary to create a non-oligomeric form
of RAD51 with an open binding site. Whilst it was
easy to design a deletion mutant that would not
oligomerise, the resulting protein was not stable and
it was not possible to purify an active form for
screening and validation.
In order to overcome these difficulties, we decided
to take advantage of the high thermal stability of
an archeal ortholog, RadA from P. furiosus, which is
structurally highly related to human RAD51 [26].
Using two parallel approaches, we have created
monomeric proteins that show a significant increase
in thermal stability and reduced propensity for
aggregation, such that they can be produced in large
quantities for structural and biophysical analysis. A
fully humanised BRC repeat binding site has been
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residue-by-residue mutagenesis or through replacing
the largeparts of thearcheal proteinwith the equivalent
region of the human protein. The resulting humanised
proteins bind the BRC4 repeat with low nanomolar
affinity in a 1:1 fashion and are suitable for ligand
binding studies using a number of biophysical
approaches. The humanised RadA proteins, being
very stable at high concentrations over a long time
scale, were employed in several biophysical assays
and in crystallography, enabling the determination of
hundreds of structures of inhibitors in complex with
a target surrogate. In addition, a reproducible FP
screening assay was developed using a chimeric
ChimRAD51 protein. Together, the chimera and
humanised RadA provided all the protein–target
forms to support a structure-driven, fragment-based
drug discovery programme that generated high-po-
tency RAD51 inhibitors (manuscripts in preparation).
Surrogate systems are not unknown in drug
discovery, but they are generally represented by either
orthologs or paralogswith high sequence identity to the
target, thus requiring little mutagenesis to become a
reliable replacement of the original protein. Kinases,
frequently the targets of inhibitor development cam-
paigns, offer good examples of chimeric surrogates.
Chimeras of PKA-PKB [41], PKA-S6K1 [42], and
PDK1-PKCζ [43] have been used to study the activity
and inhibition of PKB, S6K1, and PKCζ, respectively,
but in all cases, only a few mutations in the active site
were needed for the creation of these chimeras. In the
case of the RAD51 PPI, creating an unliganded
system with an open binding side suitable for drug
discovery presents additional challenges due to the
high affinity of the partner peptide and the apparent
obligate binding required to keep RAD51 stable. The
methodology described here should enable work on
other PPI systems, which have otherwise been
intractable to date.
Chimeric proteins have been used before to
promote the crystallisation of difficult targets and to
study their interactions with relevant inhibitors. Do-
main swapping between the bacterial and mouse
proteins made it possible to determine the structure
of the cytoplasmic domain of the eukaryotic Kir3.1
membrane channel, whereas the original mammalian
protein failed to yield crystals [44]. Loop swapping led
to the crystallisation of a chimeric phosphodiesterase
catalytic domain in complex with sidenafil and with an
inhibitory peptide, revealing important aspects in the
mechanism of phosphodiesterase 6 inhibition [45].
The same strategy was used to improve the affinity of
the Melanoma IAP protein for Caspase-9, and the
resulting chimera was then successfully used for the
development of Melanoma IAP antagonists [46,47].
Finally, humanisation of the active site of rat fatty acid
hydrolase generated a surrogate that was easy to
produce and displayed the same inhibitor sensitivity
profile as its human counterpart [48].Whilst archeal proteins are often used asmodels for
human enzymes, to our knowledge, this is the first
examplewhere an archeal protein has been used as a
basis for developing a surrogate system for drug
discovery. In contrast to the examples quoted above,
the starting point for our humanisation/chimerisation
approach was an archeal ortholog that displayed a
relatively low sequence identity with the target: 53%
overall, and even less in the target site. Nevertheless,
this thermostable protein provided a “scaffold” that
could be successfully transformed into a monomeric
protein and then reprogrammed for BRC4 binding,
without compromising higher stability with respect to
its human counterpart. Those characteristics enabled
us to overcome the limitations presented by RAD51
and thus justified the choice of such a distantly related
protein.
Whilst domain swapping with thermostable ortho-
logs is not unprecedented, this strategy does not
always lead to clear stabilisation of the mesophilic
counterpart [49]. Success of this approach was
reported with RNase H, where a stabilisation of
approximately 10 °C was achieved by replacing a
portion of the E. coli enzyme with its thermophilic
counterpart [50].
Although archeal orthologs are not necessarily
available for all potential drug targets, we believe
this is an attractive approach when such homologues
exist and particularly worth pursuing when the original
target proves difficult to handle. Also, this approach is
by no means limited to archeal surrogates. A similar
approach can also be applied to bacterial proteins and
orthologs from thermostable mycobacteria likeMyco-
bacterium hassiacum and Mycobacterium thermore-
sistibilis , whose proteins have been proposed [51,52]
and used [53,54] as surrogates for proteins from
Mycobacterium tuberculosis. As more genomic data
become available from diverse species, the sequence
space from which we can mine novel sequences with
more suitable properties for biochemical and structur-
al analysis is continuously increasing. We are not
aware of algorithms that are designed for selecting
ortholog surrogates for biochemical analysis, but this
could be a valuable resource for the research
community. Currently, the search for possible surro-
gate is done by collecting orthologous sequences and
analysing them for conservation in relevant parts of
the sequence. Tools for analysing the stability of
proteins are available [55] and could beusedaspart of
the search criteria, but eventually, the choice of a
surrogate will be based on several criteria, and the
final outcome will be a result of an empirical trial-
and-error process.
Whilst we took a stepwise approach to the
humanisation of the BRCA2 binding site on RadA in
order to build an understanding of the relationship
between protein sequence and properties such as
stability and ligand binding, the generation of a
suitable protein tool could be easily completed in
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protein mutant. At the same time, our work presented
here shows that one surrogate protein might not be
suitable for all the diverse assays and analyses that
are needed in a fragment- and structure-guided drug
discovery project. Understanding of the changes
introduced by stepwise humanisation of RadA has
facilitated the development of efficient surrogates for all
the biophysical and structural methods employed in
the project, and this alone validates the approach we
have taken (Fig. 6). In addition to providing a surrogate
system to support our structure-guided drug design,
we have also gained invaluable insight into the biology
of the target. We also report the first affinity measure-
ments of BRC4 binding to the monomeric form of
RAD51, and our stepwise humanisation has allowed
us to elucidate the effects of individual residues in the
interaction between RAD51 and BRC4 and its own
oligomerisation peptides. Given the difficulties in
working with human RAD51, our surrogate approach
has proven its value and potential not just in
approaching inhibitor studies but also in providing
valuable insight into the target, highlighting the critical
role of polar residues in RAD51–BRC4 interaction.
Materials and Methods
Cloning
All humanised RadA expression constructs were cloned
by PCR using Phusion polymerase starting from the
wild-type PfRadA sequence as the template (ENA:
AAC34998) and cloned as NcoI-XhoI fragments into the
T7-based E. coli expression vector pBAT4 [56]. The
monomeric RadA protein described here starts at aminoFig. 6. Summary of RAD51 surrogate systems. The “jigsaw
colouring illustrate the progress of humanisation and ChimRA
purposes in our drug discovery programme, as labelled in the d
than one protein or protein form is needed to enable all the di
discovery.acid 108 of the native PfRadA protein with an initiation
methionine added to its N terminus. Site-directed mutagen-
esis, including the deletion of loop L2, was performed using
the overlapping primer extension method, and the resulting
mutant constructs were cloned in a similar way into the
vector pBAT4. The ATPase domain of HsRAD51 (encoding
residues 97–339, preceded by sequence encoding for
MetGly) was cloned into the vector pBAT4 using NcoI and
Hind III restriction sites. Untagged ChimRAD51 was con-
structed by inserting the DNA encoding for residues 156–
261 of HsRAD51 (Uniprot: Q06609) between the DNA
sequence encoding for residues 108–165 and 278–349 of
PfRadA (Uniprot: O74036) and by cloning this chimeric DNA
construct into the vector pBAT4 using NcoI and XhoI
restriction sites. For the fusion constructs that include a
BRC repeat, the DNA sequence coding for the BRC4 repeat
of BRCA2 (amino acid residues 1517–1551; Uniprot:
P51587) was fused with a short linker coding for a canonical
TEV protease recognition site, and the resulting sequence
was cloned into the vector pGAT2 using BamHI and NcoI
restriction sites. The ChimRAD51 was then inserted in this
as a NcoI-XhoI fragment to create a fusion construct coding
for the protein construct His–GST–BRC4–TEV–Chim-
RAD51. For the generation of full-length ChimRAD51 and
HumRadA22 constructs, sequences coding for residues 1–
97of humanRAD51and 1–107ofPfRadAwere fused to the
5′ end of the respective monomeric constructs, and the
resulting sequences were cloned into the vector pBAT4. All
constructs were verified by automated sequencing.
Full-length RAD51 surrogates were created by adding the
human N-terminal domain and oligomerisation sequence
(residues 1–96) toChimRAD51 and the corresponding parts
of PfRadA (residues 1–107) to HumRadA22, creating
flChimRAD51 and flHumRadA22, respectively. These
were cloned into pBAT4 E. coli expression vector.
All sequences were verified by sequencing, and the
amino acid sequences for all the proteins described in this
work are provided at the end of the Supplementary Data in
FASTA format.puzzle pieces” with green (RAD51) and orange (RadA)
D51 development. Different mutants have served different
iagram. This summary illustrates our experience that more
verse analyses required for modern structure-guided drug
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All proteins were expressed in E. coli strain BL21(DE3)
carrying pUBS520 plasmid [57]. Cells were grown to an
OD600 of 0.8–1.0. For humanised RadA constructs, expres-
sion was induced by the addition of 400 μM IPTG and was
allowed to proceed for 3 h at 37 °C. For ChimRAD51
constructs, the growth temperature was reduced to 15 °C
for 1 h before the induction of expression by the addition of
400 μM IPTG and overnight incubation. Cells were pelleted
by centrifugation, resuspended in ultrapure water, and stored
at −20 °C.
Cells expressing HumRadA proteins were lysed in 20 mM
MES and 0.5 mM EDTA (pH 6.0) using an Emulsiflex C5
homogeniser. The lysate was heated to 65 °C for 15 min to
denature E. coli proteins, with the exception of the mutants
HumRadA14–33, which were not heat treated as they were
more prone to aggregation. Lysates were centrifuged at
15,000g for 30 min, and the clarified supernatant was loaded
onto a 5-ml HiTrap SP HP column (GE Healthcare). Bound
protein was eluted using a linear gradient to 500 mM NaCl in
10 column volumes. RadA mutants typically eluted at 250–
300 mMNaCl.Peak fractionswerepooled, concentrated, and
further purified by gel filtration using a Superdex 75 16/60 pg
or 26/60 pg column (GEHealthcare) equilibrated with 20 mM
Mes, 100 mM NaCl, and 0.5 mM EDTA (pH 6.0), with the
exception of mutants HumRadA5–33, which were purified in
20 mM Ches and 200 mM NaCl (pH 9.5). Peak fractions
were pooled, concentrated to 0.5 mM using 10-kDa MWCO
PES centrifugal concentrators (Millipore), flash frozen in liquid
N2, and stored in aliquots at −80 °C. The typical yield was
15–20 mg of protein from a 1 L culture of E. coli.
ChimRAD51, expressed as a fusion with His-GST-
BRC4, was purified initially using Ni Sepharose 6 Fast
Flow (GE Healthcare). This was followed by gel filtration on
a Superdex 75 16/60 pg column (GE Healthcare) in the
arginine, glutamate, and phenylalanine (“REF”) buffer
[50 mM Hepes/Na (pH 8.0), 200 mM KCl, 100 mM argi-
nine, 100 mM glutamate, and 100 mM phenylalanine] [58].
This buffer was designed to improve the long-term stability
of the protein before and after TEV protease cleavage, and
it allowed the protein to be flash frozen with liquid N2 and
stored at −80 °C until later use. ChimRAD51 was then
cleavedwith TEVprotease to release themonomeric protein
and was separated from His-GST-BRC4 fragment by
repeating the gel-filtration step. For optimal separation of
the two proteins, the loading concentration was adjusted to
obtain a GST-BRC4 peak of 1.5–2.0 AU (on a 1 cm path
length cell) at elution. For applications that demanded the
highest purity (e.g., ITC and crystal trials), purified Chim-
RAD51 monomer was loaded by syringe onto a 1 mL
Ni-Sepharose FF column equilibrated with REF buffer plus
20 mM imidazole (pH 8.0), and the flow through was
collected. This optional step removed the remaining traces
of His-tagged TEV protease and His-GST-BRC4. Before
performing ITC or FP experiments, the ChimRAD51 (1–
2 mL, 30–60 μM) was dialysed overnight at 4 °C against
20 mM K/phosphate (pH 8.0) and 192 mM KCl, changing
the buffer three times. The protein could be stored in this
buffer at 4 °C for up to aweekwith ~10% loss ofmaterial due
to aggregation per day; experimental artefacts arising from
the presence of aggregates were ameliorated by regular
filtration of the material, followed by redetermination of the
concentration with correction for the apparent absorbance
from light scattering.Full-length surrogates flChimRAD51 and flHumRadA22
were expressed in soluble form in E. coli together with
His6–MBP–BRC4 fusion constructs and were purified by a
combination of metal ion and heparin affinity chromatogra-
phies (Moschetti et al., in preparation). Both proteins eluted
early from Superdex 200 10/300 column, as reported for the
oligomeric RAD51 (data not shown).
Peptide synthesis
Peptides were synthesised by PNAC Service
(Department of Biochemistry) using standard FMOC
chemistry, except for unlabelled BRC4 repeat, which was
expressed in E. coli. All peptides were acetylated in
the N-terminus and amidated in the C-terminus. The
sequences were as follows: RadA oligomerisation peptide
Ac-NLGTFMRADEYLKKRA-NH2, RAD51 oligomerisation
peptide Ac-VPMGFTTATEFHQRRS-NH2, and BRC4 re-
peat Ac-CKEPTLLGFHTASGKKVKIAKESLDKVKNLFDE
KEQ-NH2. Fluorescently labelled BRC4 repeat was pre-
pared by reacting the synthetic peptide with an excess of
maleimide-AlexaFluor 488 dye, followedby reversed-phase
chromatography using 4.6 × 250 mm Ace C18 300 Å
column. The E. coli-produced BRC4 repeat that was
expressed as a His6–GB1 fusion with HRV 3C protease
cleavage site before the peptide, purified by Ni2+ affinity
chromatography, digested with HRV 3C protease overnight
and free peptide, and separated by reversed-phase
chromatography using a 2 ml Source RPC column (GE
Healthcare). Purified peptide was analysed and quantified
the same way as the synthetic peptides. The resulting
peptide had the sequence GPGSMSKEPTLLGFHTASGKK
VKIAKESLDKVKNLFDEKEQGSS. All peptides were char-
acterised by mass spectrometry to confirm the correct
molecular masses and incorporation of labels (when
appropriate), and their concentrations were determined
by quantitative amino acid analysis (PNAC service,
Department of Biochemistry).
ITC
ITC was performed using a Microcal itc200 instrument at
25 °C. Based on the different isoelectric points of the
mutants, proteins were dialysed either into 50 mM Tris–
HCl (pH 7.5), 150 mM NaCl, and 5 mM MgCl2 (RadA-ct,
HumRadA2, HumRadA3, HumRadA5, HumRadA16, and
HumRadA18) or into 50 mM Tris–HCl (pH 8.5), 250 mM
NaCl, and 5 mM MgCl2 (HumRadA14, HumRadA20,
HumRadA22, and HumRadA33). Experiments typically
involved titrating 20 μM of protein in the sample cell with
200 μM of BRC4 peptide in the syringe (30 μM of protein
and 300 μM of ATP for ITC involving ATP binding). The
raw ITC data were then fitted using a single-site binding
model using the Microcal ITC LLC data analysis program
in the Origin 7.0 package.
FP assay
FP binding and competition experiments were per-
formed at 25 °C in 100 mM Tris (pH 7.5), 200 mM KCl,
and 1.25% (vol/vol) glycerol. The samples were loaded
onto Costar 96-well half-area black microplates, and
fluorescence data were recorded using a PheraStar plate
4603Engineering archeal RAD51 surrogate systemsreader (BMG) equipped with polarisation filters (excitation
at 485 nm, emission at 520 nm). The concentration of
Alexa Fluor 488-labelled BRC4 peptide was constant at
10 nM, and the concentration of each protein titrant was
adjusted based on the dissociation constant observed in
trial experiments. Binding isotherms were fitted to a
standard quadratic equation for single-site binding.
Competitive binding experiments were set up with a
constant assay concentration of 10 nM Alexa Fluor 488-
labelled BRC4 peptide, and a constant assay concentration
of protein determined to give approximately 80–90%
saturation of binding in direct binding experiments. A serial
dilution of each competitor peptide was prepared and mixed
with the protein and labelled peptide, and the resulting
competitive binding isotherms were measured and fitted
using the expression described by Wang [59].
Thermal stability analysis using DSF
DSF was conducted using a BioRad CX96 or CFX
real-time PCR instruments. PfRadA mutants were buffer
exchanged into 20 mM Hepes-KOH, with same conditions
of pH and ionic strength as that for ITC (see above). Each
sample had a final volume of 100 μl and was prepared with
25 μl of 1:500 diluted fluorescent SYPROOrange dye, 65 μl
of protein solution at 4 μM final concentration, and either
10 μl of 20 mM Hepes-KOH (for the unliganded control
sample) or 10 μl of a ligand. The latter was prepared at the
following stock concentrations: 2.6 mM for each peptide
(RadA-OP, RAD51-OP, or BRC4), or 10 mM MgCl2 and
10 mM ATP. Temperature was increased from 37 °C
(310 K) to 95 °C (368 K) at a rate of 1 °C per minute. Raw
datawas resampled and converted to the negative of the first
derivative (−dRFU/dT) before the Tmwas determined as the
minimum of the negative derivative.
CD spectroscopy
We prepared 300 μl of 10 μM PfRadAmutants in 20 mM
Hepes at either pH 7.5 (HumRadA2, HumRadA5, HuR-
adA16, and HumRadA18) or at pH 8.5 (HumRadA22) with
a total ionic strength adjusted to 150 mM with NaCl. CD
spectra were measured in a Hellma Quartz Precision cell
with a 1-mm light path using Jasco J-815 CD Spectrom-
eter. The ellipicity (mDeg) of eachmutant was measured at
222 nm wavelength from 40 °C (313 K) to 95 °C (368 K),
with a temperature ramp rate of 1 °C per minute. All curves
and Tm values were fitted and derived using the Pro Fit
software using a CD thermal denaturation equation.
DLS
Average particle size and polydispersity index were
determined by DLS at 25 °C with a Zetasizer Nano Z system
(Malvern Instruments, U.K.) and were analysed using DTS
software package for Windows (version 7.11, Malvern, U.K).
Each protein was diluted to 15 μM concentration in a final
volume of 70 μL of 100 mM Tris (pH 7.5) and 200 mM KCl.
Particle scattering was recorded for the apo protein and then
for the same sample after the addition of BRC4 repeat (see
Peptide synthesis) in 1:1, 1:5, and 1:10 M excesses with
respect to the protein concentration.Crystallography
Monomeric RadA was screened for suitable crystal-
lisation conditions using Qiagen Classic and PEG suite
screens and Emerald Biosystems Wizard Screens. The
loop2 deletion mutants crystallised in most cases with
polyethylene glycol (PEG) as a precipitant, and the final
refined conditions used for structure determination are
listed in Table S1.
Crystals were cryocooled in liquid N2, and diffraction
data were collected at ESRF (Grenoble, France), Soleil
(Saint-Aubin, France) and Diamond Light Source (Harwell,
UK) synchrotron radiation sources. The data were
processed with XDS [60] or autoPROC [61] and where
applicable; scaling was performed using Scala or Aimless
[62,63]. Initial phases were obtained by molecular replace-
ment, initially using the structure of oligomeric RadA (PDB:
1PZN) as a search model using CCP4 program Amore
[64]. Later on, the high-resolution structures of the
monomeric proteins were used as search models for
new mutant structures. Structures were refined with
Refmac5 [65], phenix.refine [66], and autoBUSTER [67].
Manual real-space refinement was performed using Coot
[68]. For details on crystallographic data collection and
refinement statistics, please see Table S1.
Crystallographic fragment screen
The fragment library was obtained from Zenobia
Fragments (San Diego, USA). Unliganded crystals of
HumRadA22F were grown by mixing 2 μl of a reservoir
solution (16–20% PEG8000, 80 mM sodium cacodylate,
190 mM calcium acetate, and 20% glycerol) with 2 μl of
protein solution (as described above) and 0.5 μl of seed
stock obtained fromprevious crystals. Thesewere soaked in
cocktails of four compounds, where each compound was
present at a final concentration of 5 mM in 10% DMSO. The
crystals were soaked for approximately 24–48 h in a
hanging-drop vapour-diffusion setup. For this, 4.5 μl of the
reservoir containing 80 mM sodium cacodylate, 160 mM
calcium acetate, 18% PEG8000, and 20% glycerol was
mixed with 0.5 μl of fragment cocktail in 100% DMSO. To
avoid the loss of the thin and often not well visible
HumRadA22F crystals in conditions with compound precip-
itation, we added the fragment solution from the side of the
drop, whilst the crystal was manually transferred to the
opposite side of the drop, and the mixing of the drop was
avoided as far as possible. Structure determination and
initial ligand fitting were automated using Pipedream [67],
using the apo structure as a search model. Subsequent
refinement was performed with autoBUSTER and phenix.-
refine. Ligand restraints were calculated using grade [69] in
combination with a mySQL/ChemAxon Instant JChem
database (version 16.2.15.0, 2016, ChemAxon†) containing
the chemical fragment structures.
Accession numbersCoordinates and structure factors have been deposited
in the Protein Data Bank with accession numbers: 5FOS,
5LB2, 5LBI, 5L8V, 5LB4, 5KDD, 5J4L, 5JEE, 5JED, 5JEC,
5JFG, 5J4H, 5J4K.
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